Iskra Pusic MD

Oncology•Saint Louis, MO

Hematologic Oncology

Assistant Professor, Internal Medicine, Medical Oncology, Washington University School of Medicine

Join to View Full Profile

4500 Forest Park AveDiv IM Bone Marrow Transplant 5TH 6TH 8TH FLSaint Louis, MO 63108
Phone+1 314-454-8304
Fax+1 314-454-5902

Education & Training

SUNY Downstate Health Sciences UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 2001 - 2004
University of Zagreb Faculty of MedicineClass of 1997

Certifications & Licensure

IL State Medical License 2020 - 2026
MO State Medical License 2008 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant Start of enrollment: 2009 Dec 01
Completed
Phase 1
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
Terminated
Phase 1, Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28
Terminated
Phase 1
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
Completed
Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20
Terminated
Phase 2
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation.
Ramzi Abboud, Mark A Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao
Blood. 2025-03-27
2 citations
Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.
Joseph Pidala, Jongphil Kim, Denise Kalos, Corey Cutler, Zachariah DeFilipp
Blood Advances. 2025-03-11
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.
Meagan A Jacoby, Eric D Duncavage, Ajay Khanna, Gue Su Chang, Sridhar Nonavinkere Srivatsan
Leukemia. 2025-01-01

Abstracts/Posters

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
Iskra Pusic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

The Evolving Treatment Landscape for Patients with GvHD: More Options, More Decisions, Better Outcomes!
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Investigating the Effects of Clonal Hematopoiesis in Healthy Marrow and Blood Donors on the Outcomes of Recipients Following Hematopoietic Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Mild Covid-19 Gives Longer Lasting Immunity Than Previously Believed, Claims StudyMay 28th, 2021
$3.4 Million Aids Effort to Make a Better Flu VaccineFebruary 28th, 2019